Luteal phase after the use of LHRH agonist and antagonist

Infertility and Reproductive Medicine Clinics of North America

Volumn 12, Issue 1, 2001, Pages 163-178

  Albano, C ^a   Platteau, P ^a   Tavaniotou, A ^a   Smitz, J ^a  

^a CENTRE FOR REPRODUCTIVE MEDICINE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AZALINE B; BUSERELIN; CETRORELIX; GANIRELIX; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GOSERELIN; HUMAN MENOPAUSAL GONADOTROPIN; ITURELIX; LEUPRORELIN; LUTEINIZING HORMONE; NAFARELIN; PROGESTERONE; TEVERELIX; TRIPTORELIN; UNCLASSIFIED DRUG;

CORPUS LUTEUM FUNCTION; DRUG EFFECT; DRUG MECHANISM; ENDOMETRIUM; FEMALE; HORMONE BLOOD LEVEL; HUMAN; HYPOPHYSIS FUNCTION; LUTEAL PHASE; NIDATION; NONHUMAN; OVARY; PREGNANCY; PROGESTERONE RELEASE; REVIEW; STEROIDOGENESIS;

EID: 0035187890     PISSN: 10479422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (92)

1. Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation
2. The luteal phase of non-supplemented cycles after ovarian superovulation with human menopausal gonadotropin and the gonadotropin-releasing hormone antagonist Cetrorelix
3. Luteal phase and clinical outcome after human menopausal gonadotrophin/gonadotrophin releasing hormone antagonist treatment for ovarian stimulation in in vitro fertilization/intracytoplasmic sperm injection cycles
4. Origin of different cell types in the bovine corpus luteum as characterized by specific monoclonal antibodies
5. Prospective randomized comparison of human chorionic gonadotropin versus intramuscular progesterone for luteal phase support in assisted reproduction
6. Mechanism controlling corpus luteum function in sheep, cows, nonhuman primates and women especially in relation to the time of luteolysis
7. New antagonists of LHRH
8. The effect of hCG supplementation after combined GnRH agonist/HMG treatment in an IVF programme
9. Human endometrial maturation is markedly improved after luteal supplementation of gonadotrophin-releasing hormone analogue/human menopausal gonadotrophin stimulated cycles
10. Variations in peripheral blood levels of immunoreactive tumor necrosis factor alpha (TNFalpha) throughout the menstrual cycle and secretion of TNFalpha from the human corpus luteum
11. Specific gonadotrophin-releasing, hormone analogue binding predominantly in human luteinized follicular aspirates and not in human pre-ovulatory follicles
12. Luteal support after luteinizing-releasing hormone agonist for in vitro fertilization: Superiority of human chorionic gonadotropin over oral progesterone
13. Induction of luteolysis in the human with a long-acting analogue of luteinizing hormone-releasing factor
14. The effect of luteinizing hormone-releasing factor and its agonist on cultured human granulosa cells
15. Enhancement of human implantation by exogenous chorionic gonadotropin
16. Characterizing pituitary response to a gonadotropin-releasing hormone (GnRH) antagonist in monkeys: Tonic follicle-stimulating hormone/luteinizing hormone secretion versus acute GnRH challenge tests before, during and after treatment
17. Luteal phase support in in vitro fertilization using gonadotrophin releasing hormone analogue before ovarian stimulation: A prospective randomized study on human chorionic gonadotrophin versus intramuscular progesterone
18. Receptor-binding affinity of gonadotropin-releasing hormone analogs: Analysis by radio-ligand receptor assay
19. Absence of gonadotropin-releasing hormone receptors in human gonadal tissue
20. Disappearence of exogenously administered human chorionic gonadotropin
21. Efficacy of progesterone support in the luteal phase following in vitro fertilization and embryo transfer: Meta-analysis of clinical trials
22. Luteal rescue in in vitro fertilization and embryo transfer
23. Variations of luteinizing hormone serum concentrations after exogenous human chorionic gonadotropin administration during ovarian hyperstimulation
24. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation
25. The GnRH antagonist (Nal-Glu) acutely blocks the LH surge but allows for resumption of folliculogenesis in normal women
26. Leuprolide acetate: Serum and follicular fluid concentrations and effects on human fertilization, embryo growth, and granulosa-lutein cell progesterone accumulation in vitro
27. Expression of gonadotropin-releasing hormone (GnRH) gene in human uterine endometrial tissue
28. Establishing full-term human pregnancies using cleaving embryos grown in vitro
29. Neuroendocrine regulation of the corpus luteum in the human: Evidence for pulsatile progesterone secretion
30. Preserved pituitary response under ovarian stimulation with hMG and GnRH antagonist (Cetrorelix) in women with tubal infertility
31. Prevention of premature luteinizing hormone and progesterone rise with a gonadotropin-releasing hormone antagonist Nal-Glu, in controlled ovarian hyperstimulation
32. Synthetic analogs of luteinizing hormonereleasing hormone (LHRH) substituted in position 6 and 10
33. Failure of implantation in human in vitro fertilization and embryo transfer patients: The effect of alterated progesterone/estrogen ratios in human and in mice
34. Human chorionic gonadotrophin is a better luteal support than progesterone in ultrashort gonadotrophin-releasing hormone agonist/menotropin in vitro fertilization cycles
35. A novel regimen of gonadotropin-releasing hormone (GnRH) antagonist plus pulsatile GnRH: Controlled restoration of gonadotropin secretion and ovulation induction
36. Estrogen-induced human luteolysis
37. Effects of neutralization of luteinizing hormone on corpus luteum function and cyclicity in Macaca fascicularis
38. Effects of hCG and human pituitary LH on steroid secretion and functional life of the human corpus luteum
39. Pregnancy rate and ovarian hyperstimulation after luteal human chorionic gonadotropin in in vitro fertilization stimulated with gonadotropin-releasing hormone analogue and menotropins
40. The structure and function of the corpus luteum
41. Luteal phase defect: A review of pathophysiology
42. An intraovarian site for the luteolytic action of estrogen in the rhesus monkey
43. Expression of gap junction protein connexin-43 in the human and baboon (Papio Anubis) corpus luteum
44. Resistance to enzymatic degradation of LHRH analogs possessing increased biological activity
45. Histological evaluation of endometrium on the day of oocyte retrieval after gonadotrophin-releasing hormone agonist/follicle-stimulating hormone ovulation induction for in vitro fertilization
46. GnRH receptors in human granulosa cells: Anatomical localization and characterization by an autoradiographic study
47. Gonadotropins and estradiol responses to single intranasal or subcutaneous administration of a luteinizing hormone-releasing hormone agonist in the early follicular phase
48. The role of estrogen support during the luteal phase of in vitro fertilization - Embryo transplant cycles: A comparative study between progesterone alone and estrogen and progesterone support
49. Is there a difference in the function of granulosa-luteal cells in patients undergoing in vitro fertilization either with gonadotrophin-releasing hormon agonist or gonadotrophin-releasing hormone antagonist?
50. Agonist-induced regulation of pituitary receptors for gonadotropinreleasing hormone: Dissociation of receptor recruitment from hormone release in cultered gonadotrophins
51. Hormonal changes induced by short-term administration of gonadotropin-releasing hormone agonist during ovarian hyperstimulation for in vitro fertilization and their consequences for embryo development
52. A controlled study of luteinizing hormonereleasing hormone agonist (Buserelin) for the induction of folliculogenesis before in vitro fertilization
53. The dependency of folliculogenesis and corpus luteum function on pulsatile gonadotropin secretion in cycling women using a gonadotropinreleasing hormone antagonist as a probe
54. Gonadotropin-releasing hormone antagonist versus agonist administration in women undergoing controlled ovarian hyperstimulation: Cycle performance and in vitro steroidogenesis of granulosa-lutein cells
55. Expression of estrogen receptors α and β mRNA in corpus luteum of human subject
56. Suppression of luteinizing hormone in castrated women by the administration of human chorionic gonadotropin
57. Progesterone alone versus progesterone combined with hCG as luteal support in GnRH/hMG induced WF cycles: A randomized clinical trial
58. Dose-dependent inhibition of pituitaryovarian function during administration of a gonadotropin-releasing hormone agonist analog (Nafarelin)
59. Activation of LH receptors expressed in GnRH neurons stimulates cyclic AMP production and inhibits pulsatile neuropeptide release
60. Interleukin 1β is a potent stimulator of prostaglandin synthesis in bovine luteal cell
61. The single or dual administration of the gonadotropin-releasing hormone antagonist Cetrorelix in an in vitro fertilization embryo transfer program
62. Scheduled administration of gonadotropinreleasing hormone antagonist (Cetrorelix) on day 8 of in vitro fertilization cycles: A pilot study
63. Effects of the GnRH antagonist Cetrorelix on steroidogenesis in human granulosa lutein cells
64. Steroidogenesis in vitro of human granulosa-luteal cells pretreated in vivo with gonadotropin-releasing hormone analogs
65. Expression and regulation of gonadotropin-releasing hormone (GnRH) and GnRH receptor messenger ribonucleic acids in human granulosaluteal cells
66. Comparison of biological effects of a sustained delivery system and nonencapsulated LH-RH antagonist SB-75 in rats
67. Specific binding of luteinizing hormone releasing hormone to human luteal tissue
68. Quantitative gonadotropin-releasing hormone gene expression and immunohistochemical localization in human endometrium throughout the menstrual cycle
69. Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: An overview
70. Novel antagonists of GnRH: A compendium of their physiochemical properties, activities, relative potencies and efficacy in humans
71. Pituitary and gonadotropin hormones in women during spontaneous and induced ovulatory cycles
72. Terminology for luteinizing hormone-releasing hormone antagonists
73. Luteal phase defects induced by an agonist of luteinizing hormone-releasing factor: A model for fertility control
74. Apoptosis of human corpora lutea during cyclic luteal regression and early pregnancy
75. GnRH-mediated desensitization of pituitary gonadotrope is not calcium dependent
76. Trial of supported treatment with human chorionic gonadotrophin in the luteal phase after treatment with buserelin and human menopausal gonadotrophin in women taking part in an in vitro fertilization programme
77. Management of failed cycles in an IVF/GIFT programme with the combination of a GnRH analogue and hMG
78. The luteal phase and early pregnancy after combined GnRH-agonist/hMG treatment for superovulation in IVF or GIFT
79. Incidence of severe hyperstimulation syndrome after GnRH agonist/hMG superovulation for IVE
80. Pituitary gonadotrophin secretory capacity during the luteal phase in superovulation using GnRH-agonists and hMG in a desensitization or flare-up protocol
81. The role of luteal phase support in infertility treatment: A meta-analysis of randomized trials
82. Regulation of the menstrual cycle
83. LHRH antagonist inhibits gonadal steroid secretion in vitro
84. Suppression of luteal steroidogenesis by an LHRH antagonist (Nal-Lys antagonist: Antide) in vitro during early pregnancy in the rat
85. Receptors for luteinizing hormone-releasing hormone (LHRH) in Dunning R3327 prostate cancer and rat anterior pituitaries after treatment with a sustained dehvery system of LHRH antagonist SB-75
86. The short luteal phase
87. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle-stimulating hormone (Puregon)
88. Inhibition of human granulosa cell progesterone secretion by a gonadotropin-releasing hormone agonist
89. Endometrial evaluation by aspiration biopsy on the day of oocyte retrieval in the embryo transfer cycles in patients with serum progesterone rise during the follicular phase
90. Mechanisms regulating the menstrual cycle in women
91. Ovarian hyperstimulation for in vitro fertilization controlled by GnRH agonist administered in combination with human menopausal gonadotrophins
92. Programmed death in human ovary is a function of follicle and corpus luteum status